GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Asset Turnover

Better Therapeutics (Better Therapeutics) Asset Turnover : 0.00 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Better Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Better Therapeutics's Total Assets for the quarter that ended in Sep. 2023 was $11.16 Mil. Therefore, Better Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Better Therapeutics's annualized ROE % for the quarter that ended in Sep. 2023 was 226.28%. It is also linked to ROA % through Du Pont Formula. Better Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 was -210.05%.


Better Therapeutics Asset Turnover Historical Data

The historical data trend for Better Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Better Therapeutics Asset Turnover Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Asset Turnover
- - - -

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Better Therapeutics's Asset Turnover

For the Biotechnology subindustry, Better Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Better Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's Asset Turnover falls into.



Better Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Better Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (50.958+22.943)/ 2 )
=0/36.9505
=0.00

Better Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=0/( (11.604+10.722)/ 2 )
=0/11.163
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Better Therapeutics  (OTCPK:BTTX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Better Therapeutics's annulized ROE % for the quarter that ended in Sep. 2023 is

ROE %**(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-23.448/-10.3625
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-23.448 / 0)*(0 / 11.163)*(11.163/ -10.3625)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-1.0772
=ROA %*Equity Multiplier
=-210.05 %*-1.0772
=226.28 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Better Therapeutics's annulized ROA % for the quarter that ended in Sep. 2023 is

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-23.448/11.163
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-23.448 / 0)*(0 / 11.163)
=Net Margin %*Asset Turnover
= %*0
=-210.05 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Better Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Better Therapeutics (Better Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.
Executives
Elder Granger director 5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman officer: Chief Medical Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe director, officer: See Remarks C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry director, 10 percent owner, officer: See Remarks 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino director C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust 10 percent owner C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen officer: See Remarks 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum director, 10 percent owner, officer: Chief Executive Officer 4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu director 311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski officer: Chief Commercial Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds officer: Chief Product Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona director 1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust 10 percent owner 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104